Lipid Management in Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2013 Clinical Practice Guideline
The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
DESCRIPTION: The Kidney Disease: Improving Global Outcomes (KDIGO) organization developed a clinical practice guideline in 2013 on lipid management and treatment of all adults and children with chronic kidney disease (CKD). All forms of CKD are included (non-dialysis-dependent, dialysis-dependent, and kidney transplant recipients). METHODS: The KDIGO Lipid Guideline Development Work Group defined the scope of the guideline, gathered evidence, determined topics for systematic review, and graded the quality of evidence that had been summarized by an evidence review team. Searches of the English-language literature were conducted through August 2011 and supplemented by targeted searches through June 2013. Final modification of the guidelines was informed by the KDIGO Board of Directors and a public review process involving registered stakeholders. RECOMMENDATIONS: The full guideline includes 13 recommendations; a key element was the recommendation for statin or statin with ezetimibe treatment of adults aged 50 years or older with estimated glomerular filtration rates less than 60 mL/min/1.73 m2 but not treated with long-term dialysis or kidney transplantation. This synopsis focuses on 8 recommendations pertinent to assessment of lipid status and treatment with a statin-based regimen in adults.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Based on the evidence for lipid management in patients with CKD, the Kidney Disease: Improving Global Outcomes (KDIGO) organization developed an updated clinical practice guideline for lipid management in CKD. 399”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [399]
Citations
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Prediction of coronary heart disease using risk factor categories
Wilson, P. W. F., D’Agostino, R. B., Levy, D., Belanger, A. M., Silbershatz, H., & Kannel, W. B. (1998) · Circulation · doi:10.1161/01.cir.97.18.1837 · Cited by 9,581
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)
Authors/Task Force Members:, Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Ž., Verschuren, M., Albus, C., Benlian, P., Boysen, G., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs092 · Cited by 8,490
Stevens, P. E., Levin, A., & for the Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members* (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-158-11-201306040-00007 · Cited by 3,607
Self-citationAtorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis
Wanner, C., Krane, V., März, W., Olschewski, M., Mann, J. F. E., Ruf, G., & Ritz, E. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043545 · Cited by 2,614
Self-citationADOLESCENTS, E. P. O. I. G. F. C. H. A. R. R. I. C. A. (2011) · Pediatrics · doi:10.1542/peds.2009-2107c · Cited by 2,585
Baigent, C., Landray, M. J., Reith, C., Emberson, J., Wheeler, D. C., Tomson, C., Wanner, C., Krane, V., Cass, A., Craig, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60739-3 · Cited by 2,479
Self-citationRosuvastatin and Cardiovascular Events in Patients Undergoing Hemodialysis
Fellström, B. C., Jardine, A. G., Schmieder, R. E., Holdaas, H., Bannister, K., Beutler, J., Chae, D.-W., Chevaile, A., Cobbe, S. M., Grönhagen-Riska, C., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810177 · Cited by 2,036
Research works printed but not linked: 1
- Coresh J, 1998, J Am Soc Nephrol, 9, S24
Cited by
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw272 · Cited by 3,162
Chronic Kidney Disease Diagnosis and Management: A Review
Chen, T. K., Knicely, D. H., & Grams, M. E. (2019) · JAMA · doi:10.1001/jama.2019.14745 · Cited by 1,811
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.08.018 · Cited by 1,582
Handelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.gl · Cited by 629
Handelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.glsuppl · Cited by 559
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Banach, M., Rizzo, M., Toth, P. P., Farnier, M., Davidson, M. H., Al-Rasadi, K., Aronow, W. S., Athyros, V., Djuric, D. M., Ezhov, M. V., et al. (2015) · Archives of Medical Science · doi:10.5114/aoms.2015.49807 · Cited by 378
HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis
Palmer, S. C., Navaneethan, S. D., Craig, J. C., Johnson, D. W., Perkovic, V., Hegbrant, J., & Strippoli, G. F. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007784.pub2 · Cited by 331
Non-alcoholic fatty liver disease: an emerging driving force in chronic kidney disease
Targher, G., & Byrne, C. D. (2017) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.16 · Cited by 309
Cardiovascular Complications of Diabetic Kidney Disease
Pálsson, R., & Patel, U. D. (2014) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2014.03.003 · Cited by 292
Drawz, P., & Rahman, M. (2015) · Annals of Internal Medicine · doi:10.7326/aitc201506020 · Cited by 231
2018 Guidelines for the management of dyslipidemia
Rhee, E.-J., Kim, H. C., Kim, J. H., Lee, E. Y., Kim, B. J., Kim, E. M., Song, Y., Lim, J. H., Kim, H. J., Choi, S., et al. (2019) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2019.188 · Cited by 213
Epidemiology and Mechanisms of Uremia-Related Cardiovascular Disease
Tonelli, M., Karumanchi, S. A., & Thadhani, R. (2016) · Circulation · doi:10.1161/circulationaha.115.018713 · Cited by 213
Self-citation2018 Guidelines for the Management of Dyslipidemia in Korea
Rhee, E.-J., Kim, H. C., Kim, J. H., Lee, E. Y., Kim, B. J., Kim, E. M., Song, Y., Lim, J. H., Kim, H. J., Choi, S., et al. (2019) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2019.8.2.78 · Cited by 192
Cardiovascular disease in chronic kidney disease
Marx-Schütt, K., Cherney, D. Z. I., Jankowski, J., Matsushita, K., Nardone, M., & Marx, N. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf167 · Cited by 185
2017 Taiwan lipid guidelines for high risk patients
Li, Y.-H., Ueng, K.-C., Jeng, J.-S., Charng, M.-J., Lin, T.-H., Chien, K.-L., Wang, C.-Y., Chao, T.-H., Liu, P.-Y., Su, C.-H., et al. (2017) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2016.11.013 · Cited by 157
Banach, M., Rizzo, M., Toth, P. P., Farnier, M., Davidson, M. H., Al-Rasadi, K., Aronow, W. S., Athyros, V., Djuric, D. M., Ezhov, M. V., et al. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.1039980 · Cited by 162
Guideline Development Group., Bilo, H. J. G., Coentrão, L., Couchoud, C., Covic, A. C., SUTTER, J. D., Drechsler, C., Gnudi, L., Goldsmith, D. J. A., Heaf, J. G., et al. (2015) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfv100 · Cited by 189
Schmidt, I. M., Hübner, S., Nadal, J., Titze, S. I., Schmid, M. C., Bärthlein, B., Schlieper, G., Dienemann, T., Schultheiß, U. T., Meiselbach, H., et al. (2019) · Clinical Kidney Journal · doi:10.1093/ckj/sfz046 · Cited by 160
“lowering drugs were considered dyslipidaemic [18].”
Clinical management of the uraemic syndrome in chronic kidney disease
Vanholder, R., Fouque, D. P., Glorieux, G., Heine, G. H., Kanbay, M., Mallamaci, F., Massy, Z. A., Ortíz, A., Rossignol, P., Więcek, A., et al. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)00033-4 · Cited by 135
2015 Korean Guidelines for the Management of Dyslipidemia: Executive Summary (English Translation)
Committee for the Korean Guidelines for the Management of Dyslipidemia (2016) · Korean Circulation Journal · doi:10.4070/kcj.2016.46.3.275 · Cited by 132
Navaneethan, S. D., Bansal, N., Cavanaugh, K. L., Chang, A. R., Crowley, S. T., Delgado, C., Estrella, M. M., Ghossein, C., Ikizler, T. A., Koncicki, H. M., et al. (2024) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2024.08.003 · Cited by 126
“Unchanged from previous guidelines in 2013, 192 the KDIGO guidelines recommend initiation of statin treatment in adults with CKD not treated with dialysis or kidney transplant.”
Early Detection of CKD: Implications for Low-Income, Middle-Income, and High-Income Countries
Tonelli, M. A., & Dickinson, J. A. (2020) · Journal of the American Society of Nephrology · doi:10.1681/asn.2020030277 · Cited by 136
Self-citationEfficacy and safety of lipid lowering by alirocumab in chronic kidney disease
Toth, P. P., Dwyer, J. P., Cannon, C. P., Colhoun, H. M., Rader, D. J., Upadhyay, A., Louie, M. J., Koren, A., Letierce, A., Mandel, J., et al. (2018) · Kidney International · doi:10.1016/j.kint.2017.12.011 · Cited by 112
The Cardio-Kidney Patient: Epidemiology, Clinical Characteristics and Therapy
Schuett, K. A., Marx, N., & Lehrke, M. (2023) · Circulation Research · doi:10.1161/circresaha.122.321748 · Cited by 100
Treatment Options for Statin-Associated Muscle Symptoms
Laufs, U., Scharnagl, H., Halle, M., Windler, E., Endres, M., & März, W. (2015) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2015.0748 · Cited by 84
Relationship between chronic kidney disease and metabolic syndrome: current perspectives
Nashar, K., & Egan, B. M. (2014) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s45183 · Cited by 93
Tuñón, J., Steg, P. G., Bhatt, D. L., Bittner, V. A., Díaz, R., Goodman, S. G., Jukema, J. W., Kim, Y.-U., Li, Q. H., Mueller, C., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa498 · Cited by 76
Lipid, blood pressure and kidney update 2013
Banach, M., Serban, C., Aronow, W. S., Rysz, J., Dragan, S., Lerma, E. V., Apetrii, M., & Covic, A. (2014) · International Urology and Nephrology · doi:10.1007/s11255-014-0657-6 · Cited by 73
Visconti, L., Benvenga, S., Lacquaniti, A., Cernaro, V., Bruzzese, A., Conti, G., Buemi, M., & Santoro, D. (2016) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2016.08.002 · Cited by 82
PCSK9 in chronic kidney disease
Pavlakou, P., Liberopoulos, E. N., Dounousi, E. C., & Elisaf, M. (2017) · International Urology and Nephrology · doi:10.1007/s11255-017-1505-2 · Cited by 70
Lipid abnormalities in kidney disease and management strategies
Pandya, V., Rao, A., & Chaudhary, K. (2015) · World Journal of Nephrology · doi:10.5527/wjn.v4.i1.83 · Cited by 79
2015 Korean Guidelines for Management of Dyslipidemia
Committee for Guidelines for Management of Dyslipidemia (2015) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2015.4.1.61 · Cited by 71
Increased cardiovascular risk in patients with chronic kidney disease
Vondenhoff, S., Schunk, S. J., & Noels, H. (2024) · Herz · doi:10.1007/s00059-024-05235-4 · Cited by 67
Cardiovascular disease and chronic kidney disease
Gargiulo, R., Suhail, F., & Lerma, E. V. (2015) · Disease-a-Month · doi:10.1016/j.disamonth.2015.07.005 · Cited by 60
Meta-analysis of statins in chronic kidney disease: who benefits?
Messow, C., & Isles, C. (2017) · QJM · doi:10.1093/qjmed/hcx040 · Cited by 58
Manchikanti, L., Candido, K. D., Kaye, A. D., Boswell, M. V., Benyamin, R. M., Falco, F. J. E., Gharibo, C. G., & Hirsch, J. A. (2014) · Pain Physician · doi:10.36076/ppj.2014/17/e475 · Cited by 52
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I. M., Backer, G. D., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · Kardiologia Polska · doi:10.5603/kp.2016.0157 · Cited by 61
Kukharchuk, V. V., Владиславович, Е. М., Викторович, С. И., Arabidze, G. G., Балахонова, Т. В., Gurevich, V. S., Zelveyan, P. A., Murataliev, T. M., Myrzakhmetova, G., Александровна, С. О., et al. (2020) · Eurasian heart journal · doi:10.38109/2225-1685-2020-2-6-29 · Cited by 51
Yan, Y., Qiu, B., Wang, J., Deng, S., Wu, L., Jing, X., Du, J., Liu, Y., & She, Q. (2015) · BMJ Open · doi:10.1136/bmjopen-2014-006886 · Cited by 54
Autosomal dominant polycystic kidney disease: updated perspectives
Rastogi, A., Ameen, K. M., Baghdadi, M. A., Shaffer, K., Nobakht, N., Kamgar, M. K., & Lerma, E. V. (2019) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s196244 · Cited by 47
Diretriz Brasileira de Dislipidemias e Prevenção da Aterosclerose – 2025
Rached, F. H., Miname, M. H., Rocha, V. Z., Zimerman, A., Cesena, F. Y., Sposito, A. C., Santos, R. D., Behr, P. E. B., Bianco, H. T., Alves, R. J., et al. (2025) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20250640 · Cited by 97
López-Jiménez, F. A., Simha, V., Thomas, R. J., Allison, T. G., Basu, A., Fernandes, R., Hurst, R. T., Kopecky, S. L., Kullo, I. J., Mulvagh, S. L., et al. (2014) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2014.06.016 · Cited by 49
“These recommendations are largely congruent with those issued recently by the Kidney Disease: Improving Global Outcomes organization.(58) We recommend the continuation of statin therapy in patients with CKD undergoing hemodialysis if the treatment has been well tolerated.”
MethodVanholder, R. C., Laecke, S. V., Glorieux, G., Verbeke, F., Castillo-Rodríguez, E., & Ortíz, A. (2018) · Toxins · doi:10.3390/toxins10060237 · Cited by 48
“In contrast, this benefit of statins was less convincing in dialyzed populations [363,368–371], discouraging their initiation in ESKD, irrespective of inflammation or malnutrition, although they can be continued if already started [359].”
BackgroundShimizu, M., Furusyo, N., Mitsumoto, F., Takayama, K., Ura, K., Hiramine, S., Ikezaki, H., Ihara, T., Mukae, H., Ogawa, E., et al. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.12.013 · Cited by 50
“The importance of dyslipidemia management is also emphasized in recent clinical CKD guidelines [8].”
BackgroundGlobal cardiovascular protection in chronic kidney disease
Ruiz‐Hurtado, G., Sarafidis, P. A., Fernández‐Alfonso, M. S., Waeber, B., & Ruilope, L. M. (2016) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2016.48 · Cited by 45
Streja, E., Gosmanova, E. O., Molnar, M. Z., Soohoo, M., Moradi, H., Potukuchi, P. K., Kalantar‐Zadeh, K., & Kovesdy, C. P. (2018) · JAMA Network Open · doi:10.1001/jamanetworkopen.2018.2311 · Cited by 43
Lipid Management in Chronic Kidney Disease: Systematic Review of PCSK9 Targeting
Zheng-Lin, B., & Ortíz, A. (2018) · Drugs · doi:10.1007/s40265-017-0858-2 · Cited by 41
“These data were the basis for the current kidney disease improving global outcome (KDIGO) recommendation to initiate statins for primary prevention in all patients with CKD above the age of 50 years, and all adult CKD patients with diabetes but not on dialysis [13].”
BackgroundPelacarsen for lowering lipoprotein(a): implications for patients with chronic kidney disease
Fernández-Prado, R., Pérez-Gómez, M. V., & Ortíz, A. (2020) · Clinical Kidney Journal · doi:10.1093/ckj/sfaa001 · Cited by 42
Silbernagel, G., Fauler, G., Genser, B., Drechsler, C., Krane, V., Scharnagl, H., Grammer, T. B., Baumgärtner, I., Ritz, E., Wanner, C., et al. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.03.551 · Cited by 41
Self-citationLaufs, U., Scharnagl, H., & März, W. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000236 · Cited by 43
Practical recommendations for the management of hyperlipidemia
Fischer, S., Schatz, U., & Julius, U. (2015) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2015.02.029 · Cited by 36
The prevention and management of chronic kidney disease among patients with metabolic syndrome
Zhu, D., Judge, P. K., Wanner, C., Haynes, R., & Herrington, W. G. (2025) · Kidney International · doi:10.1016/j.kint.2024.12.021 · Cited by 36
Self-citationEffect of Statins on Renal Function in Chronic Kidney Disease Patients
Hu, P., Wu, M., Lin, T.-C., Chen, T.-T., Wu, Y., Su, S., Lu, K., Chen, J.-S., Sung, F.-C., Lee, C., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-34632-z · Cited by 36
Agrawal, H., Aggarwal, K. B., Littrell, R. L., Velagapudi, P., Turagam, M. K., Mittal, M., & Alpert, M. (2015) · Current Cardiology Reviews · doi:10.2174/1573403x1103150514155757 · Cited by 35
Lin, Y., Lai, T., Wu, H., Chou, Y., Chiang, W., Lin, S., Chen, Y., Chu, T., & Tu, Y. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1859 · Cited by 32
DEEDWANIA, P. C., Stone, P. H., Fayyad, R. S., Laskey, R. E., & Wilson, D. J. (2015) · Drugs & Aging · doi:10.1007/s40266-015-0328-z · Cited by 33
Facility-Level Variations in Kidney Disease Care among Veterans with Diabetes and CKD
Navaneethan, S. D., Akeroyd, J. M., Ramsey, D., Ahmed, S. T., Mishra, S. R., Petersen, L. A., Muntner, P., Ballantyne, C., Winkelmayer, W. C., Ramanathan, V., et al. (2018) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.03830318 · Cited by 31
Damman, K., ter Maaten, J. M., Mayne, K. J., Bolignano, D., Brown, E. M., da Costa, B. R., Dagre, A. G., Gansevoort, R. T., Gavina, C., Goette, A., et al. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag098 · Cited by 33
Młynarska, E., Budny, E., Saar, M., Wojtanowska, E., Jankowska, J., Marciszuk, S., Mazur, M., Rysz, J., & Franczyk, B. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251910429 · Cited by 31
“It is recommended that patients aged 50 years or older with CKD should be treated with a low-or moderate-dose statin, regardless of their low-density lipoprotein cholesterol level [52,53].”
BackgroundGrams, M. E., & Melamed, M. L. (2025) · Annals of Internal Medicine · doi:10.7326/annals-25-02684 · Cited by 30
Kowalski, A., Krikorian, A., & Lerma, E. V. (2014) · Europe PMC (PubMed Central) · Cited by 38
Impact of Age on the Association Between CKD and the Risk of Future Coronary Events
Tonelli, M. A., Muntner, P., Lloyd, A. M., Manns, B., Klarenbach, S. W., Pannu, N., James, M. T., & Hemmelgarn, B. R. (2014) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2014.03.013 · Cited by 28
Self-citationCardiovascular Risk and Its Presentation in Chronic Kidney Disease
Schunk, S. J., & Zimmermann, P. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14134567 · Cited by 31
Brar, S. K., Ye, F., James, M. T., Harrison, T. G., & Pannu, N. (2023) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2023.07.015 · Cited by 26
Kaseda, R., Tsuchida, Y., Yang, H.-C., Yancey, P. G., Zhong, J., Tao, H., Bian, A., Fogo, A. B., Linton, M. F., Fazio, S., et al. (2018) · BMC Nephrology · doi:10.1186/s12882-018-0814-8 · Cited by 26
Medications for Lipid Control: Statins vs Newer Drugs
McPherson, R., Adreak, N., & Sharma, A. (2024) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2024.05.004 · Cited by 33
“40”
Alsayed, N., Almahmeed, W. A., Alnouri, F., Al-Waili, K., Sabbour, H. M., Sulaiman, K., Zubaid, M., Ray, K. K., & Al‐Rasadi, K. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.11.022 · Cited by 25
Statin Therapy Before Transition to End‐Stage Renal Disease With Posttransition Outcomes
Soohoo, M., Moradi, H., Obi, Y., Rhee, C. M., Gosmanova, E. O., Molnar, M. Z., Kashyap, M. L., Gillen, D. L., Kovesdy, C. P., Kalantar‐Zadeh, K., et al. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.118.011869 · Cited by 23
Statin initiation and all-cause mortality in incident statin-naïve dialysis patients
Kim, J. E., Park, S., Kim, M.-S., Kang, S. J., Lee, J. W., Kim, K., Kim, Y. C., Kim, D. K., Joo, K. W., Kim, Y. S., et al. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.08.026 · Cited by 25
Stress Pathways in Chronic Kidney Disease: Linking Cortisol, Oxidative Stress, and Inflammation
Motrenikova, M., Boyanov, K., Bojinova, N., & Bivolarska, A. V. (2025) · Antioxidants · doi:10.3390/antiox14101259 · Cited by 22
“The coexistence of dyslipidemia with central obesity, insulin resistance, and hypertension defines the metabolic syndrome, which strongly predisposes to CKD [81,82].”
Tonelli, M. A., Tiv, S., Anand, S., Mohan, D., García-García, G., Padilla, J. A. G., Klarenbach, S. W., Blackaller, G. N., Seck, S. M., Wang, J., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.27396 · Cited by 22
Self-citationChronic kidney disease after lung transplantation in a changing era
Grootjans, H., Verschuuren, E. A. M., van Gemert, J. P., Kerstjens, H. A. M., Bakker, S. J. L., Berger, S. P., & Gan, C. T. (2022) · Transplantation Reviews · doi:10.1016/j.trre.2022.100727 · Cited by 23
Usui, T., Nagata, M., Hata, J., Mukai, N., Hirakawa, Y., Yoshida, D., Kishimoto, H., Kitazono, T., Kiyohara, Y., & Ninomiya, T. (2016) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.37044 · Cited by 25
Kim, Y., Lee, S., Lee, Y., Kang, M. W., Park, S., Park, S. H., Han, K., Paek, J. H., Park, W. Y., Jin, K., et al. (2020) · Clinical Kidney Journal · doi:10.1093/ckj/sfaa252 · Cited by 27
“Guidelines commonly considered patients with advanced CKD to be at high risk for developing atherosclerotic CVD [3, 4] and thus recommended using lipid-lowering agents for patients with nondialysis-dependent CKD Stages 3–5 irrespective of cholesterol level [5].”
BackgroundKlose, G., Beil, F. U., Dieplinger, H., von Eckardstein, A., Föger, B., Gouni‐Berthold, I., Heigl, F., Köenig, W., Kostner, G. M., Landmesser, U., et al. (2014) · Wiener klinische Wochenschrift · doi:10.1007/s00508-014-0513-9 · Cited by 22
Self-citationOrtíz, A. (2015) · Clinical Kidney Journal · doi:10.1093/ckj/sfu142 · Cited by 23
Translational science in chronic kidney disease
Sánchez-Niño, M. D., Sanz, A. B., Ramos, A. M., Ruiz‐Ortega, M., & Ortíz, A. (2017) · Clinical Science · doi:10.1042/cs20160395 · Cited by 23
Shavadia, J., Wilson, J. A., Edmonston, D. L., Platt, A. C., Ephraim, P. L., Hall, R. K., Goldstein, B. A., Boulware, L. E., Peterson, E. D., Pendergast, J., et al. (2020) · American Heart Journal · doi:10.1016/j.ahj.2020.10.055 · Cited by 21
Bittencourt, M. S., Hulten, E. A., Ghoshhajra, B. B., Abbara, S., Murthy, V. L., Divakaran, S., Nasir, K., Gowdak, L. H. W., Riella, L. V., Chiumiento, M., et al. (2015) · Kidney International · doi:10.1038/ki.2014.426 · Cited by 20
Hou, X., Wang, C., Zhang, X., Zhao, X., Wang, Y., Li, C., Li, M., Wang, S., Yang, W., Ma, Z., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0106778 · Cited by 26
“treatment has been recommended for patients with CKD according to the lipid management guidelines developed by Kidney Disease: Improving Global Outcomes (KDIGO) [8].”
BackgroundMethodHyperlipidemia and mortality in patients on peritoneal dialysis
Feng, X., Zhan, X., Wen, Y., Peng, F., Wang, X., Wang, N., Wu, X., & Wu, J. (2022) · BMC Nephrology · doi:10.1186/s12882-022-02970-w · Cited by 18
The Vitamin K Metabolome in Chronic Kidney Disease
Turner, M. E., Adams, M. A., & Holden, R. M. (2018) · Nutrients · doi:10.3390/nu10081076 · Cited by 18
“Taken together, further research is required, particularly in earlier stages of CKD where statin treatment has been shown to reduce clinical events and its use is widely supported by clinical practice guidelines [36].”
BackgroundFruchart, J., Hermans, M. P., & Fruchart‐Najib, J. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-00860-w · Cited by 19
Mark, P. B., Winocour, P. H., & Day, C. (2017) · British Journal of Diabetes · doi:10.15277/bjd.2017.125 · Cited by 18
Wang, K., Liu, Q., Mo, S., Zheng, K., Li, X., Li, J., Chen, S., Tong, X., Cao, Y. B., Li, Z., et al. (2023) · International Journal of Surgery · doi:10.1097/js9.0000000000000852 · Cited by 18
“Renal dysfunction covered prior acute and chronic renal failure, and renal dysfunction postadmi-ssion [glomerular fi ltration rate 90 ml/(min × 1.73 m 2 )] [12 – 14] .”
BackgroundInfluentialKim, S. H., Jeong, H. Y., Yang, D. H., Kim, J., & Lee, S. (2018) · Scientific Reports · doi:10.1038/s41598-018-27941-w · Cited by 16
Corcillo, A., Pivin, E., Lalubin, F., Pitteloud, N., Burnier, M., & Zanchi, A. (2017) · Swiss Medical Weekly · doi:10.4414/smw.2017.14459 · Cited by 20
Tao, Z., Luo, Z., Zou, Z., Ye, W., Hao, Y., Li, X., Zheng, K., Wu, J., Xia, J., Zhao, Y., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1580369 · Cited by 14
Statin therapy across the lifespan: evidence in major age groups
Stone, N. J., Turin, A., Spitz, J. A., Valle, C. W., & Kazmi, S. (2015) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2016.1128825 · Cited by 14
LDL-cholesterol lowering and renal outcomes
Waters, D. D. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000176 · Cited by 15
On the rationale of population screening for chronic kidney disease: a public health perspective
Bochud, M. (2015) · Public health reviews · doi:10.1186/s40985-015-0009-9 · Cited by 14
Managing dyslipidaemia in patients with chronic kidney disease
Mehta, A. (2024) · Indian Heart Journal · doi:10.1016/j.ihj.2024.01.012 · Cited by 13
Approach to Lipid Management in the Patient With Diabetes
Kim, S. J., & Subramanian, S. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf018 · Cited by 14
Levi, A., Simard, T., & Glover, C. A. (2020) · Seminars in Dialysis · doi:10.1111/sdi.12886 · Cited by 13
Insuficiencia renal crónica o enfermedad renal crónica
Boffa, J., & Cartery, C. (2015) · EMC - Tratado de Medicina · doi:10.1016/s1636-5410(15)72803-5 · Cited by 13
Zhao, Y., Liu, K., Zou, Y., Wu, Y., Yang, J., Xiao, X., Ju, X., Yang, Q., Lang, Y., & Liu, F. (2024) · Endocrine · doi:10.1007/s12020-024-03948-4 · Cited by 14
Elkoumi, O., Elkoumi, A., Elbairy, M. K., Irfan, H., Hageen, A. W., Beddor, A., Khalid, N., Mahmoud, M. A. T., Emara, A., Alkhazaleh, U., et al. (2025) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2025.07.010 · Cited by 12
Metadata
- Authors
- Tonelli, M., Wanner, C., & for the Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members*
- Affiliations
- University of Alberta (CA)
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2014-02-04
- Volume
- 160
- Issue
- 3
- Pages
- 182-189
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2159036586
- Cited by
- 226
- References
- 41
- Citations by year
- 2026: 9 · 2025: 21 · 2024: 18 · 2023: 11 · 2022: 15 · 2021: 8 · 2020: 17 · 2019: 19 · 2018: 21 · 2017: 12 · 2016: 16 · 2015: 35 · 2014: 24
- FWCI
- 28.61
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.acpjournals.org/journal/aim/text-and-data-mining (tdm)
- Locations
- Annals of Internal Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Amgen
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Nephrology › Dialysis and Renal Disease Management
- Keywords
- chronic kidney disease, lipid control, statins, ezetimibe, KDIGO guidelines, hypercholesterolemia, estimated glomerular filtration rate, dialysis, kidney transplantation, cardiovascular risk
- MeSH terms
- Adult, Algorithms, Child, Coronary Disease, Glomerular Filtration Rate, Humans, Cholesterol, LDL, Middle Aged, Risk Factors, Biomarkers, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Guideline Adherence, Dyslipidemias, Renal Insufficiency, Chronic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.